Hyperemic Efficacy of nicorandil for fractional flow reserve measurement in patients with stable coronary artery disease
Not Applicable
- Conditions
- ischemic heart disease
- Registration Number
- JPRN-UMIN000019309
- Lead Sponsor
- Chiba University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Acute coronary syndrome within the previous 1 week,vessels with prior myocardial infarction, allergy to adenosine of nicorandil,asthma or chronic obstructive pulmonary disease on medical treatment, second or third degree atrioventricular block, severe valvular heart disease, acute decompensated heart failure, reduced left ventricular function (ejection fraction less than or equal to 30%), severe liver dysfunction, severe renal insufficiency, angle-closure glaucoma, patients who are taking phosphodiesterase type 5 (PDE5) Inhibitors, pregnancy, patients who were not suitable for enrollment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method FFR value
- Secondary Outcome Measures
Name Time Method The time to hyperemia; the plateau time; fluctuation; the number of functionally significant stenoses (FFR<0.75, FFR less than or equal to 0.80); hemodynamic parameters, ECG change and symptoms during FFR measurement.